The Bremsstrahlung exposure rate from beta point source, probability of energy loss by beta during the Bremsstrahlung emission and the Bremsstrahlung activity of tissues have been calculated. The Bremsstrahlung yield for tissues in the wide energy range is also estimated from 0.01 to 100 MeV using the tabulated values given for elements by Lucien pages. The estimated Bremsstrahlung activities of pure beta nuclides in all types of tissues are extremely large (10 2 -10 6 GBq). The patients receiving such nuclides would never receive that much activity because of prohibitive radiation toxicity (few 100 MBq). Thus the patients receiving these pure beta emitting nuclides do not have to be hospitalized for radiation precautions.
Introduction
In the therapeutic nuclear medicine, application of incorporated beta-emitting radionuclides finds extremely high potential in the treatment of both malignant and non-malignant conditions. In malignant conditions tumor-specific metabolic and biological characteristics are effectively deployed to optimize the targeting of nuclides and hence permit successful therapy. In order to maximize, self-irradiation of the target region and to minimize irradiation of non-target regions, therapeutic radionuclide should emit non-penetrating radiations such as b-particles. Increasingly, pure beta emitters (Table 1) are being considered and used as therapeutic radionuclides [1, 2] . The beta-emitting nuclides are also used for therapy of non-malignant conditions such as radiosynovictomy. This includes the treatment of painful conditions associated with disease of joints such as rheumatoid arthritis or villonodular synovitis [3, 4] . After careful evaluation and diagnosis, a small amount of radioisotope is injected into the joint. These radioisotopes emit beta rays which penetrate only from fraction of a millimeter to a few millimeters and destroy the inflammatory tissue and thus reduce swelling and pain. Beta-emitting nuclides such as 90 Y, 32 P, 165 Dy etc. offer clinically proven and cost effective alternative to surgical synovictomy [5, 6] .
Uchiyama et al. [7] reported that Strontium-89 chloride is being widely used as a palliative treatment for patients with bone pain caused by bone metastases. The radionuclides such as 89 Sr and 32 P have also been successfully and effectively utilized to provide palliative therapy to patients with multifocal skeletal metastatic lesions in cases of breast and prostatic cancers. Furthermore 90 Y appears to be a potential beta-emitting radionuclide, which has been shown to offer attractive considerations for being used in radioimmunotherapy [8] . In radioimmunotherapy, beta nuclide delivers lethal dose of radiation directly to cancerous tumor cells there by reducing the radiation exposure to surrounding tissues. Beta emitting radionuclide like 32 P also finds application in infusional brachytherapy [9] . The incorporated therapeutic beta emitting nuclides produces Bremsstrahlung radiation and could have different energies and intensities. The Bremsstrahlung yield is a function of two components namely internal Bremsstrahlung and external Bremsstrahlung. The intensity of external Bremsstrahlung (EB) largely depends on the energy of the emitted beta particles and atomic number of the surrounding matrix material. On the other hand, internal Bremsstrahlung component inherently depends on the interaction of the emitted beta particle with the nucleus of the source radionuclide itself. It can therefore be stated that the photon characteristics of external Bremsstrahlung depend on the surrounding matrix material (tissue), whereas, those of internal Bremsstrahlung would depend on the emission characteristics of radionuclide.
The Bremsstrahlung component of beta emitters has been traditionally ignored in internal dosimetry calculations. This may be due to a lack of available methods for including this component in the calculations or to the belief that the contribution of this component is negligible compared to that of other emissions. The phenomenon of Bremsstrahlung production is most important at high energies and high medium atomic numbers [10] .
The radiation therapy needs experimental studies on the exposure of the Bremsstrahlung in tissues. But Markowicz et al. [11] proposed a new expression for the prediction of the Bremsstrahlung intensity (I) for compounds to take into account the self absorption and electron back scattering.
Here, Table 1 Physical properties of b-ray emitters for radionuclide therapy.
Source
Half life (in days) [12] evaluated the effective atomic number (Z eff ) of compounds for the Bremsstrahlung process using the interpolation method and reported that Z eff agrees fairly well with Z mod than Z mean .
The incorporated therapeutic beta-emitting nuclides interacts with surrounding matrix material (tissue) and produces the Bremsstrahlung radiation. The beta nuclides lose their energy during this interaction. The probability of radiative energy loss (radiative energy loss) by beta particle i during the Bremsstrahlung emission ½ðP Br Þ b i depends on modified atomic number (Z mod ) of target material (tissue) and maximum initial kinetic energy of
The modified atomic number (Z mod ) for different tissues is calculated using the composition given in the Table 2 and Eq. (2). It has been estimated ½ðP Br Þ b i using the Eq. (3) and the evaluated values of Z mod .
Specific bremsstrahlung constant (G Br )
The specific Bremsstrahlung constant is a quantity analogous to specific gamma ray constant for a radioisotope. The specific gamma ray constant is the exposure rate per unit activity at a certain distance from a source (radioisotope). Similarly, the specific Bremsstrahlung constant is the Bremsstrahlung exposure rate (in C/Kg/h) at a distance of 1 cm from a 1 MBq beta source. An estimation of specific Bremsstrahlung constant is based on mean energy, rather than the actual Bremsstrahlung spectrum. It is given by Zanzonico et al. [13] G Br ¼
where ðf b Þ i is frequency of emission (i.e., the number per nuclear transformation) of b-ray i. ½ðE Br Þ b i is the mean energy of Bremsstrahlung for b-ray i emitted by a radionuclide. It depends on [(E max ) b ] i and composition and geometry of the stopping material. Hence it is difficult to calculate precisely. In the Bremsstrahlung energy spectrum of a patient administrated by given beta nuclides, the maximum energy of the spectrum in vivo is essentially equal to one third of [(E max ) b ] i . For such distribution, the mean energy of Bremsstrahlung for ith beta particle is one third of the maximum energy of the spectrum. Hence mean energy of Bremsstrahlung for ith beta particle is given by
/MBq-h) of b-ray yielding Bremsstrahlung of mean energy ½ðE Br Þ b i . An estimation of the specific Bremsstrahlung constant is based on the Bremsstrahlung mean energy rather the actual Bremsstrahlung spectrum, is a gross approximation. The energydependent G Br ½ðE Br Þ b i corresponds to the conventional energydependent specific gamma ray constant [14] . A more accurate estimate would be obtained by replacing the Bremsstrahlung mean energy with the Bremsstrahlung energy spectrum.
Bremsstrahlung activity (A release ) Br
Bremsstrahlung activity (in MBq) is the activity of therapeutic beta nuclides below which patients can be released from medical confinement and above which patient should remain 
Estimation of Bremsstrahlung yield
Bremsstrahlung yield is a fraction of the initial energy of the electron/beta which has been transformed into Bremsstrahlung radiation after complete stopping of the electron. We have also evaluated the Bremsstrahlung yields (I Br ) of tissues for energy range from 10 keV to 100 MeV based on the Bremsstrahlung yield of five elements tabulated by Lucien Pages et al. [17] , whose atomic numbers are adjacent to the modified atomic number of compound (Z mod ) using the following Lagrange interpolation method
where lower case z is the atomic number of the element of known Bremsstrahlung yield (I Br ) z adjacent to the modified atomic number Z mod of the compound whose Bremsstrahlung yield ðI Br Þ Z mod is desired and Z is atomic number of other elements of known Bremsstrahlung yield adjacent to Z mod .
Results and discussions
The physical properties of beta emitters which are used for therapeutic purpose is shown in Table 1 . The composition of elements in soft tissues is given in Table 2 . The estimated modified atomic number (Z mod ) for all tissues defined for the Bremsstrahlung process is as shown in Table 3 . The modified atomic number (Z mod ) for all tissues (except skeleton) varies from 5.409 (for yellow marrow) to 7.497 (for spongiosa) and for skeleton tissues it varies from 7.503 (for skeleton-vertebral column (D6, L3) to 10.990 (for Skeleton-cortical bone). An estimated Bremsstrahlung exposure rate (in C/Kg/h) at a distance of 1 cm from a 1 MBq beta ray point source (G Br ) in all tissues for all therapeutic nuclides are shown in Table 4 . The exposure of Bremsstrahlung for yellow marrow is minimum compared to other tissues for all beta-therapeutic nuclides and maximum for Skeleton-cortical bone. It is found that G Br for skeletal tissues are greater than other tissues. The exposure of Bremsstrahlung is approximately equal in heart, kidney and liver for all therapeutic nuclides. For all tissues, G Br is maximum for 204 Tl beta nuclide and minimum for 89 Sr beta nuclide. The estimated probability of energy loss by all Beta particles during the Bremsstrahlung emission (P Br ) is shown in Table 5 and these values are high for skeletal tissues compared to other tissues. In all types of tissues, 90 Y beta nuclide looses more energy during the Bremsstrahlung emission compared to other nuclides. Similarly 45 Ca beta nuclide looses comparably less energy in all tissues (including skeleton tissue). For all beta nuclides probability of energy loss by beta is maximum in Skeletoncortical bone and minimum in yellow marrow. The activity of therapeutic beta nuclides above which patient should remain hospitalized on the basis of the projected Bremsstrahlung (Bremsstrahlung activity, (A release ) Br ) is as shown in Table 6 . These activities have been calculated by assuming the effective half life equals the physical half life and an exposure factor 0.25 at a distance from a patient of 1 m. For systemic radionuclide therapy, the physical half life generally over estimates the effective half life and therefore the calculated values overestimate the activities at which patients systematically administrated therapeutic radionuclide may actually be released from medical confinement. The Bremsstrahlung activity is maximum in Skeletoncortical bone and minimum in yellow marrow for all betatherapeutic nuclides. The Bremsstrahlung activity of because it decides the amount of activity essential for radiotherapy for particular region (or tissue). The estimated Bremsstrahlung yields (I Br ) as a function of energy for all types of tissues in the wide energy range from 0.01 to 100 MeV is shown in Tables 7-11 . An evaluated Bremsstrahlung yields of soft tissue is lesser than skeletal tissues because Z mod of soft tissues lesser ( o7.5) than skeleton tissue ( o10.99) due to presence of calcium in the skeleton. Thus I Br varies with energy and modified atomic number of tissue matrix. An estimated result shows that, I Br is significant at high energies. For all energies, the Bremsstrahlung yields are comparably high in Skeleton-cortical bone and low in yellow marrow. Thus the Bremsstrahlung production in skeleton tissues is greater than other tissue of different organs.
Conclusion
In all tissues, the Bremsstrahlung activity of 45 Ca is high and (Table 6 ). Thus the patients receiving these pure beta-emitting nuclides do not have to be hospitalized for radiation precautions. The Bremsstrahlung production in skeleton tissues is greater than other tissue of different organs. Hence proper localization is possible through the Bremsstrahlung imaging.
In the present estimation, it has been considered the composition of different tissues separately, which is possible to estimate the Bremsstrahlung exposure rate of individual tissue which is essential for radiotherapy. While estimating the Bremsstrahlung radiation hazard, photon yield is also important and without this it is difficult to come for conclusion.
